₹ 664.35 -0.40 (-0.06%)
- NSE
- BSE
Overview
- BSE Code 590006
- NSE Symbol AMRUTANJAN
- ISIN Demat INE098F01031
- Book Value (₹) 112.97
- Face Value (₹) 1.00
- Market Cap (₹ Cr.) 1,996.57
- P/E (TTM) 39.28
- EPS (TTM) 17.58
- Div Yield (%) 0.67
Performance
Corporate Actions
Amrutanjan Health Care Limited - Certificate under SEBI (Depositories and Participants) Regulations, 2018
Apr 07, 2025Amrutanjan Health Care Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
About Amrutanjan Health Care Ltd
The Madras-based Amrutanjan manufactures bulk drugs and drug intermediateslike theophylline, based on in-house research. Three plants have been created and deployed in the Alandur industrial belt near Madras to produce these products. It recently broadened its footprint operations into into a joint venture with Welsh firm Cardiff Chemicals to manufacture pheromones (a type of agrochemicals) at Cuddalore. Pheromones have found wide application as pesticides and are used on cotton crops.
Amrutanjan also has an agreement with a company in Philadelphia, US, to supply custom-made chemicals for exotic applications like the genetic manipulation of biological matter. It has introduced some new range of products like Pep Pill, Amrutanjan gripe water sans alcohol, Amrutanjan Maha Strong, etc. Plans are afoot to introduce analgesic and antipyretic tablets. The company also plans to launch sanitary napkins soon.
The company has approached the US FDA for approval and clearance to sell its new drugs in US. During 1996-97, it has introduced a new product called 'Cold Snap Gel' and also a mint called 'tingle'. Company having two subsidiary companies viz. Amrutanjan Drugs & Chemicals Ltd having holding stake 99.80% & Amrutanjan Finance Ltd, having holding stake is 57.26%.
Company has taken efforts to increase the export of fine chemicals & also taking major efforts to give full thrust to existing products. Amrutanjan also modernising its OTC business and expanding its export of fine chemicals which reflects to turnover & net Profit of the Company.
'Diakyur' for the treatment of Diabetes was introduced during 2000-2001 and it has been well accepted by the customers. The company's R & D has been engaged in the development of neutraceuticals.The company is mainly strategic emphasissing on Bio-Tech products and expects a good results from this division. During 2001-02 the company allotted 16,00,000 equity bonus shares of Rs.10/- each and subsequently the share capital has increased from Rs.1.60 crores to Rs.3.20 crores.
Founded | : 1936 |
Chairman | : S Sambhuprasad |
Managing Director | : S Sambhuprasad |
Address | : New 103 Old 42-45 LuzChurch Rd, Mylapore, Chennai, Tamil Nadu, 600004, |
- PAN Card
- Cancelled Cheque
- Latest 6 month Bank Statement (Only for Derivatives Trading)